AstraZeneca Pharmaceuticals LP

2744 articles about AstraZeneca Pharmaceuticals LP

• Revvity Announces New License Agreement for Next-Generation Base Editing Technology

  5/18/2023

  Revvity, Inc., announced a new license agreement with AstraZeneca for the technology underlying its Pin-point™ base editing system, a next-generation modular gene editing platform with a strong safety profile.

• 

  AstraZeneca Deepens Gene Editing Capabilities with Revvity Partnership

  5/18/2023

  Under a non-exclusive agreement, AstraZeneca is licensing biotech Revvity’s base editing technology to help create cell therapies for the treatment of cancer and immune-mediated diseases.
• 

  AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova

  5/15/2023

  The company’s second antibody-drug conjugate deal of 2023, with Shanghai-based LaNova Medicines, adds a potential first-in-class GPRC5D-directed ADC for multiple myeloma.

• LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate

  5/12/2023

  LaNova Medicines Ltd. ("LaNova Medicines") announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D).

• 

  Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm

  5/12/2023

  Nirsevimab lowered hospitalizations due to RSV-related lower respiratory tract disease by 83.21%. Friday’s data drop comes ahead of next week’s advisory committee meeting for Pfizer’s RSV hopeful.

• FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients

  5/9/2023

  AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF.

• Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund

  5/8/2023

  Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, announced that it has raised $40 million in new financing.

• 

  Biopharma Bets Big on Antibody-Drug Conjugates

  5/8/2023

  After a brief slump, interest in ADCs is at an all-time high, highlighted by a handful of recent multi-million- and billion-dollar acquisitions.
• 

  AstraZeneca, Pfizer Top 2023 Pharma List for Invention and Innovation

  5/5/2023

  Idea Pharma’s annual index reveals key drivers and metrics for large companies. AstraZeneca and Pfizer remain in the top positions this year for invention and innovation, respectively.
• 

  FDA Panel Supports Narrow Lynparza Label for Prostate Cancer

  5/1/2023

  The Oncologic Drugs Advisory Committee voted 11–1 supporting Merck’s and AstraZeneca’s PARP inhibitor for metastatic castration-resistant prostate cancer patients with BRCA mutations.
• 

  FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm

  4/27/2023

  Merck and AstraZeneca are seeking broad approval for Lynparza in mCRPC regardless of BRCA status.
• 

  Ionis and AstraZeneca Seek to Challenge Alnylam with New ATTR Data

  4/24/2023

  Eplontersen halted ATTRv-PN disease progression and improved quality of life through 66 weeks. The drug has a PDUFA date of Dec. 22, 2023.
• 

  AACR Weekend Roundup: Roche, AstraZeneca, Moderna, Merck and Affimed

  4/17/2023

  Roche, AstraZeneca, Moderna, Merck and Affimed presented new data in liver cancer, lung cancer, melanoma and lymphoma.

• IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

  4/16/2023

  Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI® in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage non-small cell lung cancer.

• Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

  4/11/2023

  Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus in the United States.

• Sobi to streamline nirsevimab contractual arrangements

  4/9/2023

  Sobi® announced a streamlining and simplification of the contractual economics for nirsevimab.

• 

  AstraZeneca’s Imfinzi/Lynparza Combo Boosts Survival in Ovarian Cancer

  4/5/2023

  AstraZeneca’s Imfinzi and Lynparza met primary endpoint markers in the Phase III DUO-O trial in advanced high-grade epithelial ovarian cancer, according to data released Wednesday.

• Compass Group and AstraZeneca Expand Activities Focused on Innovation and Shared Success

  3/29/2023

  Continuing a shared commitment to innovation, Compass Group, the world’s largest food and facility services company, and AstraZeneca, the global, science-led, patient-focused pharmaceutical company, are taking supplier management to the next level.

• Salipro Biotech publishes research in Scientific Reports on structure-function studies for membrane proteins in collaboration with AstraZeneca

  3/28/2023

  Salipro Biotech announces the publication of results from a collaboration with AstraZeneca.

• 

  AstraZeneca Notches Back-to-Back Late-Stage Wins in Lung Cancer

  3/9/2023

  AstraZeneca reported positive data from both the Phase III ADAURA trial studying Tagrisso (osimertinib) and the Phase III AEGEAN studying Imfinzi (durvalumab) in NSCLC patients.